Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

Figures & data

Table 1 Comparison of effect of vildagliptin with other antidiabetic agents on blood lipids

Study	Drug	Patient N (drug)	Comparator	Patient N (comparator)	Total cholesterol (drug/comparator)		HDL (drug/comparator)		Triglycerides (drug/comparator)
Dejager et al^Citation19	Vildagliptin	472	Placebo	160	−0.115	0.057	0.037	0.068	−0.092	0.067
Schweizer et al^Citation29	Vildagliptin	526	Metformin	254	−0.150	−0.070	−0.100	0.03	0.13	0.11
Bolli et al^Citation41	Vildagliptin	295	Pioglitazone	281	−0.165	0.19	0.015	−0.040	−0.020	0.09
Rosenstock et al^Citation61	Vildagliptin	292	Placebo	161	−0.593	0.133	0.125	0.193	−0.276	−0.308
Rosenstock et al^Citation61	Vildagliptin	154	Pioglitazone	161	−0.307	0.133	0.085	0.193	−0.145	−0.308

Abbreviations: N, number; HDL, high-density lipoprotein.

Figure 1 Effect of vildagliptin on α-cell function in hyperglycemia (A) and hypoglycemia (B).

Adapted with permission from Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078–2084.24 ©2009, The Endocrine Society.

Notes: *P = 0.019; **P = 0.039.
Abbreviation: AUC, area under the curve.

Figure 2 Instant effect of vildagliptin 100 mg/day versus placebo on glucose fluctuations.

Adapted with permission from Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249–1255.⁵² © 2007, The Endocrine Society.

Note: *P < 0.05 or better than placebo. Plasma GLP-1(A), GIP(B) during the meal tolerance test after ingestion of vildagliptin and placebo. Data are the mean± SE.
Abbreviations: GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory polypeptide.

DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res200739321822317373638

 PubMed Web of Science ®Google Scholar

SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabet Med200724995596117509069

 PubMed Web of Science ®Google Scholar

BolliGDottaFColinLMinicBGoodmanMComparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metforminDiabetes Obes Metab200911658959519515179

 PubMed Web of Science ®Google Scholar

RosenstockJKimSWBaronMAEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab20079217518517300593

 PubMed Web of Science ®Google Scholar

BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab20079241249125517244786

 PubMed Web of Science ®Google Scholar